Pricing Log in Create free account

Lexaria Bioscience Corp. (LEXX) vs Moleculin Biotech, Inc. (MBRX)

Lexaria Bioscience Corp. and Moleculin Biotech, Inc. are both Biotechnology companies. Lexaria Bioscience Corp. and Moleculin Biotech, Inc. are of similar size ($9.2M and $8.8M). Lexaria Bioscience Corp. has negative trailing earnings, so its P/E is not meaningful; Moleculin Biotech, Inc. trades at 0.0×. Across the 10 metrics below, Lexaria Bioscience Corp. leads on 6 and Moleculin Biotech, Inc. on 4.

Valuation

Metric LEXX MBRX Biotechnology median
P/E n/m 0.04 10.26
P/S 12.64 n/m 9.18
P/B 1.58 0.21 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 0.16 0.65
EV/Sales 6.08 n/m 8.98
Earnings yield (126.07%) 2,573.95% (34.89%)
Free cash flow yield (109.89%) (1,027.71%) (24.52%)

Profitability

Metric LEXX MBRX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (162.60%) (1,471.05%) (50.12%)
Return on assets (134.20%) (152.41%) (45.60%)
Return on invested capital (662.56%) (417.27%) 0.00%

Growth

Metric LEXX MBRX Biotechnology median
Revenue growth (TTM) 9.08% — 6.26%
EPS growth (last fiscal year) (40.43%) 82.01% 29.88%
Revenue growth, 5-year CAGR 17.53% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LEXX MBRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.60 0.94 4.89
Net debt to EBITDA 0.17 0.35 1.01

Dividend

Metric LEXX MBRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LEXX MBRX Biotechnology median
Market cap 8.78m 9.16m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack